Quantum BioPharma Wins FDA Clearance for Phase 2 Trial of Lucid-MS, a Potential First-in-Class Multiple Sclerosis Therapy

Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, has received U.S. Food and Drug Administration approval of its Investigational New Drug application for Lucid-MS, its lead candidate for multiple sclerosis. The clearance allows the company to proceed with a Phase 2 clinical trial, a critical step in determining whether the drug can slow or reverse myelin damage in patients. The announcement matters because it signals that a novel mechanism of action—one that does not rely on immune suppression—is advancing into mid-stage human testing, where its true potential will begin to be measured. For the roughly 2.8 million people worldwide living with MS, most existing therapies work by dampening the immune system to reduce relapses. Lucid-MS takes a different route: it is designed to protect nerve cells by inhibiting PAD2, an enzyme associated with myelin degradation. If successful, this approach could complement or even replace current treatments, particularly for patients who do not respond well to immunomodulatory drugs or who face long-term safety concerns from chronic immune suppression. The planned Phase 2 study will be randomized, double-blind, and placebo-controlled, evaluating efficacy, safety, and tolerability. Researchers will assess both clinical symptoms and changes visible through brain imaging, providing objective evidence of whether the drug alters the course of the disease. In earlier Phase 1 trials with healthy volunteers, the company reported a favorable safety profile and good tolerability, a necessary foundation before testing in patients. Quantum BioPharma, through its wholly owned subsidiary Lucid Psycheceuticals Inc., holds a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. That preclinical evidence, combined with the FDA's green light, positions Lucid-MS as a high-risk, high-reward asset in a field where true disease-modifying therapies remain elusive. The company's broader pipeline includes assets for alcohol misuse disorders and metabolic conditions, but Lucid-MS is its most advanced and closely watched program. Investors and industry observers will now look to enrollment timelines and early data readouts, which could significantly influence Quantum's valuation and partnership prospects. In the competitive MS space, where several approved drugs carry hefty price tags and administration burdens, a well-tolerated oral or injectable therapy with a distinct mechanism could capture meaningful market share. The FDA's acceptance of the IND also validates the company's preclinical work and manufacturing plans. For a small-cap biotech, achieving this milestone without a major partner is notable, though Phase 2 costs and timelines will likely require additional financing or collaboration. Quantum retains full rights to Lucid-MS and has not announced any partnership for the program. The news comes as the company also holds a stake in Unbuzzd Wellness Inc., an OTC consumer health spinoff, and royalty interests that provide non-dilutive cash flow. Still, the MS program is the primary value driver. The latest updates on QNTM are available through the company's newsroom at https://ibn.fm/QNTM. For a deeper look at the FDA clearance, the full article can be found at https://ibn.fm/g5EXE. Quantum BioPharma's progress is tracked by Quantum BioPharma (NASDAQ: QNTM). The announcement was distributed through BioMedWire, a specialized communications platform for the life sciences sector. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. The platform also offers social media distribution and a full array of corporate communications solutions to help companies reach investors and the public. More information is available at www.BioMedWire.com.